Corvus Pharmaceuticals
CRVS
102 hedge funds and large institutions have $307M invested in Corvus Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 13 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 17
84% more capital invested
Capital invested by funds: $167M → $307M (+$140M)
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
41% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $1.62M
11% more funds holding
Funds holding: 92 → 102 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.36% less ownership
Funds ownership: 61.29% → 55.93% (-5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.42M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.75M |
| 3 |
Goldman Sachs
New York
|
+$1.41M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.15M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$979K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$3.03M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.01M |
| 3 |
Morgan Stanley
New York
|
-$1.42M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$807K |
| 5 |
Renaissance Technologies
New York
|
-$661K |
CRVS Hedge Fund Activity: Q3 2025 in Review
102 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2025, worth a combined $307M — up 84% from $167M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CRVS positions and 13 closed out — a net gain of 10 holders — while 34 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $2.42M. The largest seller was DCF Advisers, exiting entirely with an estimated $3.03M sold.
- 102 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2025, up from 92 in Q2 2025.
- Funds reported $307M of Corvus Pharmaceuticals stock for Q3 2025, up 84% quarter-over-quarter.
- 23 funds opened new Corvus Pharmaceuticals positions in Q3 2025 and 13 closed out, a net change of +10 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2025 was BlackRock, an estimated $2.42M added.
- The largest Corvus Pharmaceuticals seller in Q3 2025 was DCF Advisers, an estimated $3.03M sold.
Based on aggregated 13F filings for Q3 2025.